Omada Health vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Omada Health is a virtual-first chronic care platform for diabetes, hypertension, and musculoskeletal conditions serving 2,000+ employer and health plan customers, with $170M 2024 revenue and a June 2025 Nasdaq IPO (OMDA).
About
Omada Health is a San Francisco-based digital health company founded in 2012 that offers virtual-first care programs for chronic conditions including prediabetes, Type 1 and Type 2 diabetes, hypertension, and musculoskeletal disorders. The platform combines human health coaches, licensed clinical practitioners, and connected devices—including cellular-enabled scales and continuous glucose monitors—with behavior science and clinical protocols to deliver personalized, data-driven care at scale. Omada describes its approach as "Compassionate Intelligence," integrating human relationships with AI-driven personalization.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.